|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Mylan N.V. (MYL) signed an agreement with the U.S. Department of Justice (DOJ) and two other relators to finalize the Medicaid drug rebate settlement worth $465 million, announced in Oct 2017.
In 2Q17, Bristol-Myers Squibb’s (BMY) Opdivo generated revenues of around $1.2 billion, which reflected ~45% growth on a year-over-year basis.
Firms with a structural cost advantage can either undercut competitors on price while earning similar margins, or they can charge market-level prices while earning relatively high margins.